

U.S. Multiple Myeloma Market

Description: The Frost & Sullivan research titled U.S. Multiple Myeloma Market provides pipeline analysis, revenue forecasts, treatment trends, and patient forecasts. In this research service, Frost & Sullivan's expert analysts thoroughly examine the drivers, challenges, strategies, and treatment trends affecting the market.

Market Sectors

Expert Frost & Sullivan analysts thoroughly examine the following market sectors in this research:

By Application:

- First-line Hematopoietic Stem Cell Transplant (HSCT) Eligible
- First-line Non-HSCT Eligible
- Second-line Therapy
- Third+-line Therapy

Technologies

The following technologies are covered in this research:

- **Chemotherapy:** Chemotherapy drugs use a variety of different mechanisms and are considered the mainstay of cancer treatment, exhibiting successful treatment for decades. These drugs unfortunately affect normal cells as well as cancer cells. The resulting inhibition of normal cells causes a variety of side effects including nausea, hairloss, increased infections, and neuropathy. As a result, chemotherapy drugs have to be carefully monitored for the production of side effects, with grade 3 and 4 side effects considered severe, often resulting in a dose reduction for the patient.
- **Hematopoietic Stem Cell Transplant (HSCT):** HSCT is the therapy of choice for most blood cancer treatments. It provides the best opportunity for a patient to achieve a complete response by removing the damaged and abnormal stem cells and replacing them with autologous (cells from self) or allogenic (from donor) hematopoietic stem cells.
- **Targeted Therapies:** Targeted therapies work by attacking a specific metabolic pathway within cancer cells and leave non-cancer cells relatively unharmed. These drugs can selectively target enzymes, CD markers or receptors that are distinct to blood cancer cells.

Contents:

1. Executive Summary
 - 1. Executive Summary
 - 1. Executive Summary
2. Market Introduction
 - 1. Research Scope and Methodology
 - 1. Scope and Segmentation
 - 2. Research Methodology
 - 2. Blood Cancer Overview
 - 1. Blood Cancer Biology
 - 2. Blood Cancer Definitions
 - 3. Multiple Myeloma Overview
 - 1. Etiology
 - 2. Staging and Prognostic Factors
 - 3. Treatment Overview
 - 4. Patient Forecasts
 - 1. Prevalence
 - 2. Incidence
 - 3. Mortality

- 4. Staging
- 5. General Market Trends
- 1. Industry Challenges and Strategies
- 2. Market Drivers

- 3. Product and Pipeline Analysis
 - 1. Approved Product Analysis
 - 1. Chemotherapy Product Analysis
 - 3. Steroid Product Analysis
 - 4. Interferon Product Analysis
 - 5. Immunomodulatory Product Analysis
 - 2. Pipeline Analysis
 - 1. Chemotherapy Pipeline Analysis
 - 2. Targeted Therapy Late Stage Pipeline Analysis
 - 3. Targeted Therapy Early Stage Pipeline Analysis
 - 4. Supportive Product Pipeline

- 4. Competitive Analysis
 - 1. Introduction
 - 1. Treatment Trends
 - 2. Market Engineering Measurements
 - 3. Common Drug Regimens
 - 4. Drug Prices
 - 2. Market Revenue Forecasts
 - 1. Total Market Revenue Forecasts
 - 2. First-line HSCT Eligible Revenue Forecasts
 - 3. First-line HSCT Non-Eligible Revenue Forecasts
 - 4. Second-line Revenue Forecasts
 - 5. Third-line+ Revenue Forecasts
 - 6. Market Share Analysis
 - 3. Product Revenue Forecasts
 - 1. Alkeran
 - 2. Doxil
 - 3. Revlimid
 - 4. Thalomid
 - 5. Velcade
 - 6. Tanespimycin
 - 7. ZIO-101
 - 8. Perifosine

- 5. Appendix
 - 1. Decision Support Databases
 - 1. Physicians
 - 2. Government Healthcare Expenditure
 - 3. Private Healthcare Expenditure
 - 4. Pharmaceutical R&D Expenditure
 - 5. Percent Pharmaceutical R&D Expenditure

List of Figures

Chapter 2

Multiple Myeloma Market: Durie-Salmon and ISS Staging (U.S.), 2006
Multiple Myeloma Market: Newly Diagnosed Patients by Sex (U.S.), 2003-2013
Multiple Myeloma Market: Newly Diagnosed Male Patients by Age (U.S.), 2003-2013
Multiple Myeloma Market: Newly Diagnosed Female Patients by Age (U.S.), 2003-2013
Multiple Myeloma Market: Patient Deaths by Sex (U.S.), 2003-2013
Multiple Myeloma Market: Male Patient Deaths by Age (U.S.), 2003-2013
Multiple Myeloma Market: Female Patient Deaths by Age (U.S.), 2003-2013
Multiple Myeloma Market: Impact of Top Industry Challenges (U.S.), 2007-2013
Multiple Myeloma Market: Impact of Top Market Drivers (U.S.), 2007-2013

Chapter 3

Multiple Myeloma Market: Product Analysis for Alkeran (U.S.), 2006
Multiple Myeloma Market: Product Analysis for Doxil (U.S.), 2006
Multiple Myeloma Market: Product Analysis for Velcade (U.S.), 2006
Multiple Myeloma Market: Product Analysis for Revlimid (U.S.), 2006
Multiple Myeloma Market: Product Analysis for Thalomid (U.S.), 2006
Multiple Myeloma Market: Chemotherapy Pipeline Overview (U.S.), 2006
Multiple Myeloma Market: Targeted Therapy Late-stage Pipeline Overview (U.S.), 2006
Multiple Myeloma Market: Targeted Therapy Early-stage Pipeline Overview (U.S.), 2006

Chapter 4

Multiple Myeloma Market: Most Common Drug Regimens (U.S.), 2006
Multiple Myeloma Market: Average Cost per Cycle by Drug (U.S.), 2006
Multiple Myeloma Market: Total Market Revenue Forecasts (U.S.), 2003-2013
Multiple Myeloma Market: Revenue Forecasts for First-line HSCT Eligible Therapy (U.S.), 2005-2013
Multiple Myeloma Market: Revenue Forecasts for First-line HSCT Non-eligible Therapy (U.S.), 2005-2013
Multiple Myeloma Market: Revenue Forecasts for Second-line Therapy (U.S.), 2005-2013
Multiple Myeloma Market: Revenue Forecasts for Third-line+ Therapy (U.S.), 2005-2013
Multiple Myeloma Market: Company Market Share by Revenues (U.S.), 2006
Multiple Myeloma Market: Company Market Share by Revenues (U.S.), 2013
Multiple Myeloma Market: Revenue Forecasts for Doxil (U.S.), 2003-2013
Multiple Myeloma Market: Revenue Forecasts for Revlimid (U.S.), 2006-2013
Multiple Myeloma Market: Revenue Forecasts for Thalomid (U.S.), 2003-2013
Multiple Myeloma Market: Revenue Forecasts for Velcade (U.S.), 2003-2013
Multiple Myeloma Market: Revenue Forecasts for Tanespimycin (U.S.), 2010-2013
Multiple Myeloma Market: Revenue Forecasts for ZIO-101 (U.S.), 2012-2013
Multiple Myeloma Market: Revenue Forecasts for Perifosine (U.S.), 2013

Ordering: Order Online - <http://www.researchandmarkets.com/reports/455656/>

Order by Fax - using the form below

Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

Fax Order Form

To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit

<http://www.researchandmarkets.com/contact/>

Order Information

Please verify that the product information is correct and select the format(s) you require.

Product Name: U.S. Multiple Myeloma Market
Web Address: <http://www.researchandmarkets.com/reports/455656/>
Office Code: SCUULLV6

Product Formats

Please select the product formats and quantity you require:

	Quantity	
Electronic (PDF) - Site License:	<input type="checkbox"/>	EUR 4906
Electronic (PDF) - Enterprisewide:	<input type="checkbox"/>	EUR 6132
Electronic and Hard Copy (PDF) - Enterprisewide:	<input type="checkbox"/>	EUR 6541 + EUR 50 Shipping/Handling
Electronic and Hard Copy (PDF) - Site License:	<input type="checkbox"/>	EUR 5315 + EUR 50 Shipping/Handling

* Shipping/Handling is only charged once per order.

Contact Information

Please enter all the information below in **BLOCK CAPITALS**

Title: Mr Mrs Dr Miss Ms Prof

First Name: _____ Last Name: _____

Email Address: * _____

Job Title: _____

Organisation: _____

Address: _____

City: _____

Postal / Zip Code: _____

Country: _____

Phone Number: _____

Fax Number: _____

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)



Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

- Pay by credit card:
 - American Express
 - Diners Club
 - Master Card
 - Visa

Cardholder's Name _____

Cardholder's Signature _____

Expiry Date _____ | _____

Card Number _____

CVV Number _____

Issue Date _____ | _____

(for Diners Club only)

- Pay by check:

Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

- Pay by wire transfer:

Please transfer funds to:

Account number	833 130 83
Sort code	98-53-30
Swift code	ULSBIE2D
IBAN number	IE78ULSB98533083313083
Bank Address	Ulster Bank, 27-35 Main Street, Blackrock, Co. Dublin, Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: _____

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at <http://www.researchandmarkets.com/info/terms.asp>

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World